** Drug developer Sangamo Therapeutics' shares SGMO.O fall 47.4% to $1.23 in extended trading
** SGMO said that Pfizer PFE.N terminated partnership to develop hemophilia A gene therapy
** Co's collaboration and license agreement with Pfizer will terminate, effective April 21, 2025
** In July, PFE announced positive results from a late-stage study of therapy
** SGMO said it plans to explore all options to commercialize the hemophilia A gene therapy, including seeking a new partner
** Up to Monday's close, SGMO is up 330.7% YTD
(Reporting by Rishi Kant in Bengaluru)
((Rishi.Kant@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。